The company released positive long-term data from the phase I/II study onits adeno-associated virus 8 (AAV8) gene therapy candidate, DTX401, ...
https://www.google.com/url?rct=j&sa=t&url=https://www.nasdaq.com/articles/ultragenyx-rare-presents-preliminary-2020-revenues-guidance-2021-01-12&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNHg1XcoNf-aqf5OZXcV4Z-WtzBGtg
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.